Wikipedia

Glysobuzole

(Redirected from Draft:Glysobuzole)

Glysobuzole (or isobuzole) is an oral antidiabetic drug, it is taken once daily by oral administration and it is water soluble to become pharmaceutically active within the gastrointestinal tract. It is a sulfonamide derivative that is similar to sulfonylureas. Glysobuzole has antihyperglycemic activity, so it is able to lower blood glucose levels by increasing the release of insulin from the pancreatic beta cells. Glysobuzole functions as a modulator in metabolic processes involving insulin and therefore it is used to treat diabetes.[1]

Glysobuzole
Names
Preferred IUPAC name
4-Methoxy-N-[5-(2-methylpropyl)-1,3,4-thiadiazol-2-yl]benzene-1-sulfonamide
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C13H17N3O3S2/c1-9(2)8-12-14-15-13(20-12)16-21(17,18)11-6-4-10(19-3)5-7-11/h4-7,9H,8H2,1-3H3,(H,15,16)
    Key: LZCBNYVJTNCPDR-UHFFFAOYSA-N
  • CC(C)CC1=NN=C(NS(=O)(=O)C2=CC=C(C=C2)OC)S1
Properties
C13H17N3O3S2
Molar mass 327.4 g/mol
Density 1.338 g/cm3
Boiling point 486.5 °C at 760 mmHg
Hazards
Flash point 248 °C (478 °F; 521 K)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Structure and reactivity

edit

The molecular formula of glysobuzole is C13H17N3O3S2. It is synonymously found under the name isobuzole. Its systematic name is 4-methoxy-N-[5-(2-methylpropyl)-1,3,4-thiadiazol-2-yl]benzenesulfonamide. Its achiral structure includes a benzene ring connected to a thiadiazole via a sulfonamide. The thiadiazole is bound to an iso-butyl group. The molecular weight is 327.427 Dalton.

Synthesis

edit

The general pathway of synthesizing sulfonamides is through a substitution reaction involving an amine and a sulfonyl chloride. Alternatively, this can be done with sulfonate esters and ammonia. However, no literature can be found on such an alternative pathway for the synthesis of glysobuzole.[2] The synthesis of glysobuzole involves three reagents: p-anisylsulfonyl chloride, thiosemicarbazide and isovaleric acid.[3]

 
Structure of isovaleric acid
 
Structure of thiosemicarbazide

Thiosemicarbazide will form the five-membered ring in the structure. Before the cyclization of thiosemicarbazide, it will first undergo acylation to form a monothiodiacylhydrazine. This happens under the influence of a carboxylic acid such as isovaleric acid. The acid will donate an acyl group to the thiosemicarbazide. The intermediate compound cyclizes under the influence of an acid catalyst.

A compound very similar to glysobuzole is glybuzole. The two compounds both contain a hypoglycemic part, which are structurally identical. The synthesis pathway of glysobuzole is very similar to the synthesis pathway of glybuzole. For both compounds, the reaction is a bimolecular substitution reaction (SN2). When synthesizing glybuzole, pyridine is added as an oxidation step at the end of the reaction.[4] The intermediate compound will have a positive charge. Pyridine takes up the oxygen to remove the positive charge present on the nitrogen atom.

Mechanism of action

edit

Due to the hypoglycemic activity of glysobuzole it is used to treat type 2 diabetes by raising the plasma insulin levels and, effectively, lowering the blood glucose levels. Glysobuzole binds to sulfonylurea-specific receptors on pancreatic β-cells and blocks the ATP-dependent channels for potassium. The inflow of K+ ions stops and the cell membrane depolarizes, resulting in the diffusion of calcium into the cell. The actomyosin filaments of β-cells contract and release insulin. Secretion of insulin in large amounts decreases the concentration of glucose in blood.[5]

Metabolism

edit

After oral intake, glysobuzole is absorbed in the intestine. Metabolism takes time to come into effect, therefore the drug should be ingested 30 minutes before a meal. It binds to plasma proteins and induce their biological effect on the body.[5] Afterwards, they undergo N-acetylation and oxidation, and are exerted from the body through the urinary tract.

Efficacy

edit

Apart from their hypoglycemic activity, sulfonamides, including glysobuzole, show bacterial resistance. They are competitive inhibitors of folic acid synthesis preventing the reproduction and growth of microbes, making them bacteriostatic agents. Therefore, they are the first successful antibacterial drugs used in infections.[6]

Adverse effects

edit

If glycemic control has not been reached after 2 weeks, the dosage should be increased, this can be done until control is reached. However, there is the danger of excessive dosages, as a result, this can lead to hypoglycemia caused by abnormal insulin production. Insulin induction by glysobuzole is independent of the glucose levels which only increases the risk of lowering the blood sugar below normal. Moreover, it can lead to weight gain, nausea, skin irritation and, very rarely, photosensitivity.[5] Some patients become susceptible to urinary tract infections, after one incident the likelihood of another increases, therefore it can further lead to a urinary tract disorder. This is caused by metabolite precipitation due to acetylated sulfonamides in the urinary tract.[7]

Toxicity

edit

The six membered benzene ring causes skin sensitization.[8] The sulfonyl nitrate part of the compound causes ocular toxicity.[9]

Acute toxicity data - lethal dose

edit
type of test[10] species route of exposure dose toxic effects
LD50 rodent - rat oral 534 mg/kg details of toxic effects not reported other than lethal dose value
LD50 rodent - mouse oral 468 mg/kg details of toxic effects not reported other than lethal dose value
LD50 rodent - mouse intraperitoneal 250 mg/kg behavioral - ataxia; endocrine - hypoglycemia; nutritional and gross metabolic - body temperature decrease
LD mammal - dog oral >1 gm/kg behavioral - tremor, muscle weakness; gastrointestinal - nausea or vomiting

Tumorigenic data

edit
type of test species route or exposure dose toxic effects
TDLo - Lowest published toxic dose rodent - rat oral 214 gm/kg/52W-C tumorigenic - equivocal tumorigenic agent by RTECS criteria; kidney, ureter,  bladder - tumors[11]

References

edit
  1. ^ "Glysobuzole". pubchem.ncbi.nlm.nih.gov.
  2. ^ Smith, Michael, October 17- (2016). Organic chemistry : an acid-base approach (Second ed.). Boca Raton, FL. ISBN 978-1-4822-3826-6. OCLC 1030993177.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)
  3. ^ Molbase Glysobuzole
  4. ^ "Thieme Pharmaceutical Substances". pharmaceutical-substances.thieme.com. Retrieved 2021-06-05.
  5. ^ a b c Sola, Daniele; Rossi, Luca; Schianca, Gian Piero Carnevale; Maffioli, Pamela; Bigliocca, Marcello; Mella, Roberto; Corlianò, Francesca; Fra, Gian Paolo; Bartoli, Ettore; Derosa, Giuseppe (2015). "State of the art paper Sulfonylureas and their use in clinical practice". Archives of Medical Science. 4 (4): 840–848. doi:10.5114/aoms.2015.53304. ISSN 1734-1922. PMC 4548036. PMID 26322096.
  6. ^ Tacic, Ana; Nikolic, Vesna; Nikolic, Ljubisa; Savic, Ivan (2017). "Antimicrobial sulfonamide drugs". Adv Techn Advanced Technologies. 6 (1): 58–71. doi:10.5937/savteh1701058T. ISSN 2406-2979. OCLC 7080287268.
  7. ^ Tacic, Ana; Nikolic, Vesna; Nikolic, Ljubisa; Savic, Ivan (2017). "Antimicrobial sulfonamide drugs". Adv Techn Advanced Technologies. 6 (1): 58–71. doi:10.5937/savteh1701058T. ISSN 2406-2979. OCLC 7080287268.
  8. ^ Cronin, M. T. D.; Basketter, D. A. (September 1994). "Multivariate Qsar Analysis of a Skin Sensitization Database". SAR and QSAR in Environmental Research. 2 (3): 159–179. doi:10.1080/10629369408029901. ISSN 1062-936X. PMID 8790644.
  9. ^ Tilden, Morris E. (1991-01-01). "Systemic Sulfonamides as a Cause of Bilateral, Anterior Uveitis". Archives of Ophthalmology. 109 (1): 67–69. doi:10.1001/archopht.1991.01080010069035. ISSN 0003-9950. PMID 1987952.
  10. ^ "3567-08-6". www.chemsrc.com.
  11. ^ "3567-08-6". www.chemsrc.com.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Glysobuzole&oldid=1212963779"